Clinical Research Directory

Inclusion Criteria: Only the patients meeting all the following criteria can be eligible to participate in the trial: * Fully informed consent and signed ICF; * Age of 18-75 years; * Histologically and/or cytologically confirmed advanced or recurrent stage III B-C or IV (AJCC Version 8) NSCLC with TKI-resistant EGFR-mutated tumors, which also satisfy following conditions: Without T790M mutation in exon 20 after 1st or 2nd generation EGFR-TKI (eg, gefitinib, erlotinib, icotinib, afatinib,etc.) treatment failure;If with T790M mutation in exon 20 after 1st or 2nd generation EGFR-TKI (eg, gefitinib, erlotinib, icotinib, afatinib,etc.),participants are required to have osimertinib or other 3rd generation EGFR-TKI treatment failure prior to enrollment.Participants with osimertinib treatment failure as 1st line therapy (regardless of their EGFR T790M mutation status);Previous neoadjuvant/adjuvant chemotherapy is allowed, but the time interval between the last dose of chemotherapy and recurrence/metastasis must be at least 6 months. * With at least one measurable disease per RECIST 1.1; * Agree to provide formalin fixed tumor specimen after EGFR-TKI treatment failure or provide fresh biopsy tissue; * ECOG performance status of 0-1; * Life expectancy ≥ 3 months; * Good organ function; * Any adverse event resulting from prior treatment, surgery, or radiotherapy must return to grade 0 or 1 according to NCI-CTCAE v5.0, except for alopecia of any grade; * Willing and able to follow protocol visits, treatment plans, laboratory tests and other study procedures; * Women of childbearing potential must have negative serum pregnancy test within 3 days prior to the first dose of investigational product: Exclusion Criteria: * Exclusion of tumor histology or cytology confirmed the presence of small cell lung cancer components, or squamous cell carcinoma components of more than 10%; * Combined with other driver mutations with known therapeutic drug, including but not limited to: ALK rearrangement, ROS1 mutation, BRAF600E mutation; * Previous systematic chemotherapy for advanced NSCLC; * Subjects with no measurable lesions; * Subjects with cancer meningitis and spinal cord compression; * Subjects with untreated central nervous system (CNS) tumor metastasis; * Subjects were previously treated with an anti-PD-1, anti-PD-L1 or anti-CTLA-4 agent; * Subjects with any active, known or suspected autoimmune disease; * Subjects who are now participating in other clinical studies or the last dose of prior investigational drug was given in \< 4 weeks (or 5 half-lives) from the first investigational product administration of this study; * Subjects who were expected to receive any other antitumor therapy (eg, other maintenance therapy for NSCLC, radiotherapy, and/or surgical excision); * Subjects who received major surgery within 4 weeks prior to enrollment or were not fully recovered from prior surgery; * Subjects with other malignancies requiring concurrent treatment; * Subjects with grade II or above myocardial ischemia or myocardial infarction, or subjects with arrhythmia with poor control; * Subjects with uncontrolled pleural/pericardial effusion, or with ascites requiring repeated drainage; * Subjects with uncontrolled tumor-related pain; * Subjects with severe allergic reactions to other monoclonal antibodies and subjects with severe allergic reactions to pemetrexed, platinum or its prophylaxis; * Subjects with psychological disorder, alcohol alcoholism, drug abuse or drug dependency